NEW YORK (360Dx) – French diagnostic and theranostics firm Theradiag announced on Wednesday that it has signed an agreement to supply its Lisa Tracker monitoring kits for use in monitoring responses to biosimilar drugs sold by French generic drug maker Biogaran.
Lisa Tracker kits are designed to monitor serum levels of circulating TNF-alpha, prescribed TNA-alpha inhibitors, and drug-neutralizing antibodies to help physicians manage treatment regimens.
Under the agreement, Biogaran will reference Lisa Tracker kits with the drugs it supplies in France, which include Remsima, a biosimilar of the monoclonal antibody-based immunosuppressant Remicade (infliximab). Additional terms were not disclosed.
"This deal with Biogaran will enable us to supply our Lisa Tracker kits with all the infliximabs on the market and also for other monoclonal antibodies," Theradiag CEO Michel Finance said in a statement.
In December, Merck's French subsidiary signed a deal to reference Lisa Tracker in contracts to supply Remicade.